As per the research report, the Middle East and Africa Apheresis Market was worth USD 0.16 billion in 2022 and estimated to be growing at a CAGR of 6.86%, to reach USD 0.22 billion by 2027.
The increasing prevalence of chronic diseases, the growing demand for plasma from biopharmaceutical companies, large patient base, trauma and injury cases, more demand for blood diagnosis, and the ever-increasing number of surgeries and favorable reimbursements in the region are primarily accelerating the growth rate of the apheresis market in the Middle East and Africa. According to the 2019 World Federation of Hemophilia report, the number of people identified as having hemophilia increased from 78,630 in 2000 to 324,700 in 2020 worldwide. In addition, approximately 157,520 people worldwide have hemophilia A and around 32,000 people have hemophilia B. All these factors mentioned above are estimated to have a healthy growth for the MEA apheresis market during the forecast period.
Technological advancements in the development of newer apheresis techniques in clinically ill patients are increasing day by day, as primary therapy or as an adjunct to other treatments for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic syndrome, drug toxicity, autoimmune diseases, sepsis, uremia, and hepatic failure. Additionally, according to the report from CDC, it can be estimated that over 45 million adults suffer from chronic kidney disease. Apheresis help in the purification of blood for patients suffering from kidney disorders. In a recent study, the prevalence of renal diseases seen among UAE residents was over 4.5% in males and 2.9% in females. While in the Kingdom of Saudi Arabia, the prevalence of chronic kidney disorder in the Saudi population was recorded at around 5.8%. Along with these factors, the increasing number of product approvals and innovations has driven the growth of the MEA apheresis market.
However, the inherent high cost of apheresis therapy is expected to hamper the growth of the MEA apheresis market during the forecast period. In addition, the risks associated with apheresis such as complications related to fluid transfer, side effects related to the use of fresh frozen plasma (FFP), risk of hepatitis or allergic reactions, or hypoglycemia due to the use of large amounts of citrate, all these factors are also expected to limit the growth of the market in the years to come. Furthermore, the shortage of blood donors and skilled technicians in some rural MEA regions also holds back the market's growth.
This research report on the Middle East and Africa Apheresis Market has been segmented and sub-segmented into the following categories:
By Product:
By Procedure:
By Application:
By Technology:
By End User:
By Country:
The private sector plays a key role in bankrolling the healthcare sector in Africa, with more than 50% of their investment. The apheresis market is growing slowly because of many problems the region faces, battles, and the unstable economy. However, countries like the USA, China, and the UK are investing in the region, and this increased financial revenue will aid the healthcare sectors in this region. This region has a global share of 8% and has a CAGR of 6.86%.
In 2020, the Kingdom of Saudi Arabia dominated the MEA market for apheresis and will continue to be a significant share during the analysis period. The sustained increase in demand for blood components, high incidence of chronic diseases such as cardiovascular disease, leukemia, and sickle cell anemia, large population, are increasing the demand for apheresis in the region. In addition, the constant shortage of blood and the need to ensure the safety of the blood supply also prompts a focus on blood by apheresis.
The regional market in African countries is expected to see growth attributed to the growing awareness regarding the advantages of apheresis over whole blood collection and the increasing demand for plasma from biopharmaceutical companies. In addition, the promising outlook for the African region is mainly due to the rising prevalence of blood-related disorders in developing economies.
Meanwhile, the United Arab Emirates remains the market showing the highest growth rate in the MEA apheresis market due to factors such as increased patient spending, reimbursement policies, and growing patient awareness. Government support, availability of skilled professionals, and the demand for advanced blood collection technologies support market growth in this region. In addition, the market has seen growth in the past several years thanks to greater willingness to donate blood and safety precautions during the procedure.
KEY MARKET PLAYERS:
Companies playing a prominent role in the MEA apheresis market profiled in the report are Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, Terumo BCT, Inc., Fresenius Medical Care, Kawasumi Laboratories Inc., Cerus Corporation, HemaCare Corporation, Kaneka Corporation, B. Braun Melsungen AG, and Nikkiso Co., Ltd., Therakos, Inc., and Medica S.p.A.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Apheresis devices
5.1.2.1 Plasma separators
5.1.2.2 Plasma component separators
5.1.2.3 Immunoadsorption Columns
5.1.2.4 Plasma Perfusion Columns
5.1.2.5 Hemoperfusion Columns
5.1.3 Apheresis disposables
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Procedure
5.2.1 Introduction
5.2.2 Donor Apheresis
5.2.3 Therapeutic Apheresis
5.2.4 Y-o-Y Growth Analysis, By Procedure
5.2.5 Market Attractiveness Analysis, By Procedure
5.2.6 Market Share Analysis, By Procedure
5.3 Application
5.3.1 Introduction
5.3.2 Renal Diseases
5.3.3 Neurology
5.3.4 Cancer
5.3.5 Hematology
5.3.6 Autoimmune Diseases
5.3.7 Cardiovascular Diseases
5.3.8 Y-o-Y Growth Analysis, By Application
5.3.9 Market Attractiveness Analysis, By Application
5.3.10 Market Share Analysis, By Application
5.4 Technology
5.4.1 Centrifugation
5.4.1.1 Intermittent Flow
5.4.1.2 Continuous Flow
5.4.2 Membrane Separation
5.4.3 Y-o-Y Growth Analysis, By Technology
5.4.4 Market Attractiveness Analysis, By Technology
5.4.5 Market Share Analysis, By Technology
5.5 End user
5.5.1 Introduction
5.5.2 Private Blood Collection Centres
5.5.3 Public Blood Collection Centres
5.5.4 Hospitals
5.4.5 Y-o-Y Growth Analysis, By End user
5.4.6 Market Attractiveness Analysis, By End user
5.4.7 Market Share Analysis, By End user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Procedure
6.1.3.4 By Application
6.1.3.5 By Technology
6.1.3.6 By End user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Procedure
6.1.4.4 By Application
6.1.4.5 By Technology
6.1.4.6 By End user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Procedure
6.1.5.4 By Application
6.1.5.5 By Itechnology
6.1.5.6 By End user
6.2 Middle-East
6.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Asahi Kasei Medical Co., Ltd.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Haemonetics Corporation
8.3 Terumo BCT, Inc.
8.4 Fresenius Medical Care
8.5 Kawasumi Laboratories Inc.
8.6 Cerus Corporation
8.7 Hemacare Corporation
8.8 Kaneka Corporation
8.9 Braun Melsungen AG
8.10 Nikkiso Co., Ltd.
8.11 Therakos, Inc.,
8.12 Medica S.p.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
